Navigation Links
Diabetes drug shows promise in reducing risk of cancer
Date:11/23/2011

EAST LANSING, Mich. An inexpensive drug that treats Type-2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State University researcher.

The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides biological evidence for previously reported epidemiological surveys that long-term use of the drug metformin for Type-2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.

The research appears in the current edition of PLoS One.

"People with Type-2 diabetes are known to be at high risk for several diabetes-associated cancers, such as breast, liver and pancreatic cancers," said Trosko, a professor in the College of Human Medicine's Department of Pediatrics and Human Development. "While metformin has been shown in population studies to reduce the risk of these cancers, there was no evidence of how it worked."

For the study, Trosko and colleagues focused on the concept that cancers originate from adult human stem cells and that there are many natural and man-made chemicals that enhance the growth of breast cancer cells.

Using culture dishes, they grew miniature human breast tumors, or mammospheres, that activated a certain stem cell gene (Oct4A). Then the mammospheres were exposed to natural estrogen a known growth factor and potential breast tumor promoter and man-made chemicals that are known to promote tumors or disrupt the endocrine system.

The team found that estrogen and the chemicals caused the mammospheres to increase in numbers and size. However, with metformin added, the numbers and size of the mammospheres were dramatically reduced. While each of the chemicals enhanced growth by different means, metformin seemed to be able to inhibit their stimulated growth in all cases.

"While future studies are needed to understand the exact mechanism by which metformin works to reduce the growth of breast cancers, this study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers," he said.

"Though we still do not know the exact molecular mechanism by which it works, metformin seems to dramatically affect how estrogen and endocrine-disrupting chemicals cause the pre-existing breast cancers to grow."

In addition, further research needs to be done with human cultures to see if metformin can reduce the risk of pancreatic and liver cancers in Type-2 diabetics as well, he said.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert

Related medicine news :

1. Van Andel Institute study may lead to better, safer drug for diabetes
2. American Diabetes Associations preferred testing method fails to identify kids with diabetes
3. Hispanics With Diabetes Urged to Get Yearly Foot Care
4. Canadian Diabetes Association announces Elsevier as new publisher of Canadian Journal of Diabetes
5. MU researchers develop tool that saves time, eliminates mistakes in diabetes care
6. Molecular link between diabetes and cancer described
7. Risk of contracting diabetes to increase in world of 7 billion people
8. Intensive Control of Type 1 Diabetes Helps Kidneys: Study
9. Intensive diabetes therapy protects Type 1 diabetics kidneys
10. Which diabetes drug is best for diabetics with kidney disease?
11. Early, intensive therapy for type 1 diabetes prevented kidney disease in long-term study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... 2017 , ... SensorInsight ®, an Internet of Things ... U.S.A. to offer Internet of Things (IoT) solutions based on Libelium ... such as monitoring solutions used to detect potentially hazardous conditions in urban areas, ...
(Date:1/17/2017)... Mass. (PRWEB) , ... January 17, 2017 , ... ... company to visualize, detect, and eliminate cyber threats in real-time, today announced a ... Solutions provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , ... announced a new agreement as part of a long-term extension of their media ... includes the airing of some of the sport’s premier events exclusively on FloWrestling.com as ...
(Date:1/16/2017)... ... January 16, 2017 , ... Gym Source, America’s leading retailer of premium residential ... Hanover, New Jersey. , “We are elated to be opening this new showroom,” explains ... designed to give clients a seamless and motivating shopping experience.” , Every fitness journey ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... SCOTTSDALE, Ariz. , Jan. 17, 2017 ... retired US Navy Capt. Mark Kelly as ... (ACMA) 2017 National Conference in Washington D.C. ... shuttle commander, will speak on Friday morning, April 21 ... management professionals from across the country are expected to ...
(Date:1/17/2017)... Jan. 17, 2017  Market Research Future published a Half Cooked ... is expected to reach USD 33.6 million during the period 2016 ... Highlights ... Endoscopy Devices Market has been examined as a swiftly growing market ... huge demand for endoscopy device in various regions.  The increasing growth ...
(Date:1/17/2017)... NEW YORK , Jan. 17, 2016  Attorney Advertising ... on behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or ... encouraged to obtain additional information and assist the investigation by ... investigation concerns whether Anthera and certain of its officers and/or ... Exchange Act of 1934. ...
Breaking Medicine Technology: